Tg Therapeutics Stock News

TG Therapeutics Inc (NASDAQ: TGTX) shares are trading significantly lower Monday morning after the company announced it has voluntarily withdrawn the pending Biologics License Application/supplement

TG Therapeutics Inc's (NASDAQ: TGTX) new data showed that ublituximab /Ukoniq, dubbed U2, had an elevated risk of death in the phase 3 Unity combo trial or chronic lymphocytic leukemia (CLL) and sm

Company voluntarily withdraws UKONIQ® from sale for approved indications of relapsed/refractory MZL and FL Company to host conference call, Monday, April 18, 2022 at 8:30 AM ET NEW YORK, April 15, 2

NEW YORK, April 06, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that data from the ULTIMATE I & II Phase 3 trials evaluating ublituximab in patients with relapsi

NEW YORK, April 04, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced data from the ULTIMATE I & II Phase 3 trials evaluating ublituximab in patients with relapsing fo

Biopharma stocks are sensitive to a key binary event called the PDUFA date, the date by which the Food and Drug Administration is required to give its verdict on a regulatory application filed with it

FDA schedules ODAC meeting for April 22, 2022 FDA schedules ODAC meeting for April 22, 2022

In the last trading session, 1.34 million shares of the TG Therapeutics Inc. (NASDAQ:TGTX) were traded, and its beta was 2.21. Most recently the company’s share price was $8.49, and it changed around -$0.18 or -2.08% from the last close, which brings the market valuation of the company to $1.29B. TGTX currently trades at a … Why TG Therapeutics Inc. (NASDAQ: TGTX) Stock Should Not Be Discarded By Investors In 2022 Read More »

NEW YORK, March 04, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations, including one oral and three poster presentations, highlighti

The U.S. Food and Drug Administration ((FDA)) has extended the review date of TG Therapeutics'' <> applications seeking approval of ublituximab plus UKONIQ (umbralisib) to…

The FDA has extended the review period of TG Therapeutics Inc''s (NASDAQ: TGTX ) biologics license application and supplemental New Drug Application for ublituximab in combination with Ukoniq (umbralisib) for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The Prescription Drug User Fee Act (PDUFA) goal date is postponed to June 25. The FDA notified the Company … Full story available on Benzinga.com

The FDA has extended the review period of TG Therapeutics Inc's (NASDAQ: TGTX) biologics license application and supplemental New Drug Application for ublituximab in combination with Ukoniq (umbra

The Food and Drug Administration approval calendar was light in February. Nevertheless, the month saw regulatory nods accorded to some breakthrough therapies. Agios Pharmaceuticals, Inc.'s (NASDAQ: AG

TG Therapeutics (TGTX) delivered earnings and revenue surprises of -12.90% and 76.56%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?